{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:33:57Z","timestamp":1784950437231,"version":"3.55.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Malignant pertussis, the most severe manifestation of <jats:italic toggle=\"yes\">Bordetella pertussis<\/jats:italic> infection, is characterized by multiple organ failure and a high mortality rate despite advanced intensive care measures. Hyperleukocytosis is the hallmark of malignant pertussis and necessitates urgent and aggressive interventions. Among the therapeutic options, leukoreduction via whole blood exchange (BE) transfusion has been associated with significant procedural risks and potential clinical deterioration. Hydroxyurea was recently proposed as a pharmacological alternative for leukoreduction. This study reports our clinical experience with hydroxyurea as an alternative to BE in managing infants with malignant pertussis admitted to a PICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Prospective case series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>A referral PICU in France.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Critically ill infants (<jats:italic toggle=\"yes\">n<\/jats:italic> = 27) with severe pertussis infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>Hydroxyurea therapy or BE transfusion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>We reviewed all critically ill infants admitted to our unit for severe pertussis between January 2017 and July 2024. The primary outcome was 28-day survival, and the secondary outcome was the efficacy of hydroxyurea on blood leukocyte count reduction. Among the 27 infants admitted for severe pertussis, 12 exhibited features of malignant pertussis. Of these, seven were treated with hydroxyurea and five with BE. The majority of infants were term and under 3 months old. All patients required ventilatory support, with eight on invasive mechanical ventilation and three receiving extracorporeal membrane oxygenation therapy. Overall mortality was three of 12 (25%). Hydroxyurea was administered at a dose of 20\u2009mg\/kg\/d for a median duration of 12 days. Hyperleukocytosis was successfully reduced within 7 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Hydroxyurea is an alternative therapy for malignant pertussis infection that can efficiently address hyperleukocytosis with limited mortality.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000001218","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:00:33Z","timestamp":1739379633000},"page":"e1218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Hydroxyurea for Malignant Pertussis in Critically Ill Children"],"prefix":"10.1097","volume":"7","author":[{"given":"Matthieu","family":"Blanc","sequence":"first","affiliation":[{"name":"IHU-PROMETHEUS Comprehensive Sepsis Center and Pediatric Intensive Care, Neonatal Medicine, and Pediatric Emergency Department, AP-HP Paris Saclay University, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Marais","sequence":"additional","affiliation":[{"name":"IHU-PROMETHEUS Comprehensive Sepsis Center and Pediatric Intensive Care, Neonatal Medicine, and Pediatric Emergency Department, AP-HP Paris Saclay University, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Debs","sequence":"additional","affiliation":[{"name":"IHU-PROMETHEUS Comprehensive Sepsis Center and Pediatric Intensive Care, Neonatal Medicine, and Pediatric Emergency Department, AP-HP Paris Saclay University, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir L.","family":"Cousin","sequence":"additional","affiliation":[{"name":"IHU-PROMETHEUS Comprehensive Sepsis Center and Pediatric Intensive Care, Neonatal Medicine, and Pediatric Emergency Department, AP-HP Paris Saclay University, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5423-5532","authenticated-orcid":false,"given":"Pierre","family":"Tissi\u00e8res","sequence":"additional","affiliation":[{"name":"IHU-PROMETHEUS Comprehensive Sepsis Center and Pediatric Intensive Care, Neonatal Medicine, and Pediatric Emergency Department, AP-HP Paris Saclay University, Bic\u00eatre Hospital, Le Kremlin-Bic\u00eatre, France."},{"name":"Institute of Integrative Biology of the Cell, CNRS, CEA, Paris Saclay University, Gif-sur-Yvette, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Paris Saclay Neonatal and Pediatric ICU Research Alliance (PANDORA) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"R1-20250212","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S1473-3099(17)30390-0","article-title":"An update of the global burden of pertussis in children younger than 5 years: A modelling study.","volume":"17","author":"Yeung","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R2-20250212","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/civ472","article-title":"Associated with infant deaths from pertussis: A case-control study.","volume":"61","author":"Winter","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R3-20250212","doi-asserted-by":"crossref","first-page":"e8823","DOI":"10.1097\/MD.0000000000008823","article-title":"Severe pertussis infection: A clinicopathological study.","volume":"96","author":"Palvo","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R4-20250212","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/INF.0000000000000577","article-title":"Predictors of disease severity in children hospitalized for pertussis during an epidemic.","volume":"34","author":"Marshall","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20250212","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/PCC.0000000000001013","article-title":"Identifying children at risk of malignant Bordetella pertussis infection.","volume":"18","author":"Ganeshalingham","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"R6-20250212","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/PCC.0b013e31828a70fe","article-title":"Critical pertussis illness in children: A multicenter prospective cohort study.","volume":"14","author":"Berger","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R8-20250212","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s001340000587","article-title":"Is leukocytosis a predictor of mortality in severe pertussis infection?","volume":"26","author":"Pierce","year":"2000","journal-title":"Intensive Care Med"},{"key":"R9-20250212","doi-asserted-by":"crossref","first-page":"ftw087","DOI":"10.1093\/femspd\/ftw087","article-title":"Pertussis leukocytosis: Mechanisms, clinical relevance and treatment.","volume":"74","author":"Carbonetti","year":"2016","journal-title":"Pathog Dis"},{"key":"R10-20250212","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/vox.13722","article-title":"Biological impact of manual blood exchange in malignant Bordetella pertussis infection in infants.","volume":"119","author":"Cousin","year":"2024","journal-title":"Vox Sang"},{"key":"R11-20250212","doi-asserted-by":"crossref","first-page":"e816","DOI":"10.1542\/peds.2009-2860","article-title":"Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants.","volume":"126","author":"Rowlands","year":"2010","journal-title":"Pediatrics"},{"key":"R12-20250212","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/genes12071096","article-title":"Hydroxyurea\u2014the good, the bad and the ugly.","volume":"12","author":"Musia\u0142ek","year":"2021","journal-title":"Genes (Basel)"},{"key":"R13-20250212","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/ccr3.3264","article-title":"Leukoreduction and hydroxyurea in malignant pertussis: A case series.","volume":"8","author":"Aldairi","year":"2020","journal-title":"Clin Case Rep"},{"key":"R14-20250212","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fped.2018.00261","article-title":"Leukemoid reaction in infant pertussis: Is there a place for hydroxyurea? A case report.","volume":"6","author":"Maitre","year":"2018","journal-title":"Front Pediatr"},{"key":"R15-20250212","doi-asserted-by":"crossref","first-page":"578244","DOI":"10.1016\/j.jneuroim.2023.578244","article-title":"Hydroxyurea interaction with \u03b17 nicotinic acetylcholine receptor can underlie its therapeutic efficacy upon COVID-19.","volume":"385","author":"Lykhmus","year":"2023","journal-title":"J Neuroimmunol"},{"key":"R16-20250212","doi-asserted-by":"crossref","first-page":"11512","DOI":"10.1074\/jbc.M113.506121","article-title":"Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran\/basal cell adhesion molecule (Lu\/BCAM) through phosphodiesterase 4A activation.","volume":"289","author":"Chaar","year":"2014","journal-title":"J Biol Chem"},{"key":"R17-20250212","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2172-12-28","article-title":"Nitric oxide\/cGMP pathway signaling actively down-regulates \u03b14\u03b21-integrin affinity: An unexpected mechanism for inducing cell de-adhesion.","volume":"12","author":"Chigaev","year":"2011","journal-title":"BMC Immunol"},{"key":"R18-20250212","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","article-title":"A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.","volume":"8","author":"Pule","year":"2015","journal-title":"Expert Rev Hematol"},{"key":"R19-20250212","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial.","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"R20-20250212","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2217\/fmb.09.133","article-title":"Pertussis toxin and adenylate cyclase toxin: Key virulence factors of Bordetella pertussis and cell biology tools.","volume":"5","author":"Carbonetti","year":"2010","journal-title":"Future Microbiol"},{"key":"R21-20250212","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1111\/j.1742-4658.2011.08237.x","article-title":"The ins and outs of pertussis toxin.","volume":"278","author":"Locht","year":"2011","journal-title":"FEBS J"},{"key":"R22-20250212","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/archdischild-2019-317862","article-title":"Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease.","volume":"105","author":"van Geyzel","year":"2020","journal-title":"Arch Dis Child"},{"key":"R23-20250212","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/hematology.2019000053","article-title":"Sickle cell disease: A comprehensive program of care from birth.","volume":"2019","author":"de Montalembert","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R24-20250212","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG).","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"R25-20250212","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1097\/MD.0000000000000215","article-title":"From infancy to adolescence: Fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.","volume":"93","author":"Hankins","year":"2014","journal-title":"Medicine (Baltim)"},{"key":"R26-20250212","doi-asserted-by":"crossref","first-page":"e27022","DOI":"10.1002\/pbc.27022","article-title":"Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.","volume":"65","author":"Rodriguez","year":"2018","journal-title":"Pediatr Blood Cancer"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:00:42Z","timestamp":1739379642000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000001218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000001218","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}